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Introduction
Dermatomyosis (DM) is a rare autoimmune myopathy involving 
a violation of  the skeletal muscles and skin. It may be associ-
ated with cancer in adults. We report a serie of  9 cases to discuss 
the clinical feature, paraclinical, therapeutic and evolving our case 
paraneoplastic DM (PDM) from the literature. 
Material and methods
We retrospectively reviewed the clinical records of  all patients 
hospitalized for DM in dermatology department at university 
hospital HASSAN II Fez during the period 2007-2015, including 
the case of  DMP were selected.
Results
9 patients were included for this study among 25 patients with 
DM usually 36% of  DM paraneoplastic (Figure 1), with 3 cases 
of  nasopharyngeal carcinoma, 3 cases of  breast cancer and one 
case of  multiple myeloma, a case of  gastric lymphoma, and one 
case of  cancer rectum (Figure 2). Le sex ratio F / H was 3.5, the 
mean age was 48.6 years (38-65 years). The DM was indicative 
of  neoplasia in all cases after a mean period of  7 months with 
an average time to diagnosis of  DM 11.8 months (4-27 months).
Skin involvement was present in all patients. The mode of  revela-
tion was muscular in 14 cases. The demonstrations were extra-
muscular type of  lung disease (3 cases), articular (3 cases) and 
gastrointestinal (5 cases). Muscle enzymes were elevated in all pa-
tients, and the inflammation was present in 4 cases. In all cases 
no noted vasculitis dermal in histology. The treatment was based 
on prolonged corticosteroid therapy and synthetic antimalarials 
drugs in all cases and the management of  associated cancer. The 
evolution was marked by clinical and laboratory remission in 1 
case after 2 years of  decline, death in one patient, 4 patients are 
being monitored and 3 patients were lost to follow (Figure 3, 4).
Discussion
Dermatomyositis (DM) is a rare, autoimmune disease of  the con-
nective, which is associated with immune complex deposi¬tion 
and subsequent inflammatory cell accumulation [1]. The incidence 
rate of  tumors in patients with DM has been reported to display 
a variable frequency of  0.6-1.0 per 100,000 individuals [2]. Diag-
nosis of  dermatomyositis is associated with a higher risk of  ma-
lignances, including the ovary, lung, pancreas, stomach, colorectal 
cancer and non-Hodgkin lymphoma particularly for patients aged 
>40 years [3]. Approximately 30% of  the patients are left with 
mild to severe disability though the prognosis has been obviously 
improved. Age and association with tumor are risk factors associ-
ated with poor prognosis. DM often presents as a paraneoplastic 
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Abstract
Dermatomyositis, a rare inflammatory disease possibly of  autoimmune origin, produces a characteristic skin rash and sym-
metrical proximal myopathy. Patients with Dermatomyositis have a higher incidence rate of  cancer, compared with the general 
population, since DM usually presents as a paraneoplastic syndrome. through the study of  9 cases of  paraneoplastic dermato-
myositis we will discuss the clinical feature, paraclinical, etiological, therapeutic and outcomes of  paraneoplastic dermatomy-
ositis (PDM) relative to the literature.
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syndrome, thus implying the presence of  a tumor [4]. A probable 
hypothesis for the development of  DM is that shared immuno-
logical processes link malignancy with myopathy [5]. 
A diagnosis of  adult dermatomyositis compels us to exclude a 
possible paraneoplastic etiology. According to the largest series, 
15% to 25% of  cases of  adult dermatomyositis are associated 
with cancer however our series is characterized by the high fre-
quency of  malignancy (36%) [3, 6]. This risk is present even in 
cases of  amyopathic dermatomyositis [7, 8].
The DM can precede, coincide with, or develop after the diag-
nosis of  cancer [9]. In our case the DM was revealing where the 
breast and nasopharyngeal were the most frequent. This neoplas-
tic association with poor prognosis hence the importance of  early 
diagnosis. The pathogenesis is multifactorial and some clinical or 
laboratory criteria are suggestive. We discovered cases of  DMP 
advanced stage in our series despite the absence of  neoplasia cri-
teria. No consensus exists regarding the extent or frequency of  
the balance sheet to achieve in a subject with DM. The agents 
Figure 1. Percentage Dermatomyositis Paraneoplastic.
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Figure 2. Various Malignancies Associated with Dermatomyositis Encountered During the Study.
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Figure 3. Erythro Facial Edema in a Patient with Paraneoplastic Dermatomyositis.
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including corticosteroids and immunosuppressive drugs are al-
ways used in the treatment of  dermatomyositis. The purposes of  
treatment are to improve the ability of  daily living by increasing 
muscle strength and to alleviate extramuscular manifestations, in-
cluding rash,dysphagia, dyspnoea, arthralgia and fever. But The 
treatment of  DMP is based on the treatment of  tumor underlying 
and immunosuppressants, however, the development of  targeted 
therapies could change this therapeutic approach in the near fu-
ture.
Conclusion
The PDM is frequent hence the interest to recall the need for a 
full investigation before each case DM even outside predictive of  
neoplasia signs.
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Figure 4. The Heat Erythema of  Paraneoplastic Dermatomyositis.
